You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 29, 2024

Details for Patent: 9,744,126


✉ Email this page to a colleague

« Back to Dashboard


Title:Controlled release corticosteroid compositions and methods for the treatment of otic disorders
Abstract: Disclosed herein are compositions and methods for the treatment of otic disorders with steroid, NSAID, and/or adenosine triphosphatase ("ATPase") modulator agents. In these methods, the steroidal, NSAID, and/or ATPase compositions and formulations are administered locally to an individual afflicted with an otic disorder, through direct application of these compositions and formulations onto or via perfusion into the targeted auris structure(s).
Inventor(s): Lichter; Jay (Rancho Santa Fe, CA), Trammel; Andrew M. (Olathe, KS), Piu; Fabrice (San Diego, CA), Ye; Qiang (San Diego, CA), Dellamary; Luis A. (San Marcos, CA), Lebel; Carl (Malibu, CA), Harris; Jeffrey P. (La Jolla, CA)
Assignee: Otonomy, Inc. (San Diego, CA) The Regents of the University of California (Oakland, CA)
Filing Date:Jun 09, 2014
Application Number:14/300,030
Claims:1. An intratympanic composition for use in the treatment of an otic disorder, the intratympanic composition comprising a multiparticulate anti-inflammatory corticosteroid in the form of micronized and non-coated particles; and an auris acceptable gel; wherein the auris acceptable gel is an auris acceptable hydrogel; and the intratympanic composition has a pH between 7.0 and 8.0.

2. The intratympanic composition of claim 1, wherein the auris acceptable gel has a gelation viscosity between about 15,000 cP and about 1,000,000 cP.

3. The intratympanic composition of claim 1, wherein the auris acceptable gel is capable of being injected by a 18-31 gauge needle or cannula through the tympanic membrane to an area on or near the round window membrane.

4. The intratympanic composition of claim 1, wherein the intratympanic composition has an osmolarity of from about 100 mOsm/L to about 1000 mOsm/L.

5. The intratympanic composition of claim 1, wherein the composition comprises between 1-70 mg/mL of the multiparticulate anti-inflammatory corticosteroid.

6. The intratympanic composition of claim 1, wherein the anti-inflammatory corticosteroid is dexamethasone, dexamethasone ester, or pharmaceutically acceptable salt thereof.

7. The intratympanic composition of claim 1, wherein the anti-inflammatory corticosteroid is methylprednisolone, or pharmaceutically acceptable salt thereof.

8. The intratympanic composition of claim 1, wherein the anti-inflammatory corticosteroid is prednisolone, or pharmaceutically acceptable salt thereof.

9. The intratympanic composition of claim 1, wherein the otic disorder is selected from Meniere's disease, Autoimmune ear disease (AIED), otitis media, acoustic trauma induced sensorineural hearing loss, drug induced sensorineural hearing loss, sensorineural hearing loss due to infection, idiopathic sensorineural hearing loss, vertigo, tinnitus, and combinations thereof.

10. The intratympanic composition of claim 9, wherein the otic disorder is Meniere's disease.

11. The intratympanic composition of claim 9, wherein the otic disorder is tinnitus.

12. The intratympanic composition of claim 1, wherein sustained release of the anti-inflammatory corticosteroid into the cochlea occurs for a period of at least 10 days after a single administration.

13. The intratympanic composition of claim 1, wherein sustained release of the anti-inflammatory corticosteroid into the cochlea occurs for a period of at least 14 days after a single administration.

14. An intratympanic composition for use in the treatment of an otic disorder, the composition comprising: from 4.5 wt % to 6 wt % multiparticulate dexamethasone in the form of micronized and non-coated particles; from 14 wt % to 16 wt % poloxamer; and water, wherein the composition has a pH of 7.0-7.8, an osmolarity of270-320 mOsm/L, and a gelation temperature of 20-30.degree. C.

15. The intratympanic composition of claim 14, wherein the multiparticulate dexamethsone is micronized dexamethasone.

16. The intratympanic composition of claim 14, wherein the poloxamer is poloxamer 407.

17. The intratympanic composition of claim 14, wherein sustained release of dexamethasone into the cochlea occurs for a period of at least 14 days after a single administration.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.